+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 90Years
All Genders
ID05065216

Adaptive Randomized Study Evaluating DM199 Compared to Placebo for Treatment of Moderate Acute Ischemic Stroke

Led by DiaMedica Therapeutics Inc · Updated on 2026-09-14

728

Participants Needed

86

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of DM199 rinvecalinase alfa in adults who have experienced an acute ischemic stroke due to small and medium vessel blockages. This Phase 23 randomized, double-blind, placebo-controlled study focuses on patients with moderate stroke severity who present within 24 hours of stroke onset and have limited treatment options. Participants undergoing mechanical thrombectomy or those who received fibrinolytics without persistent neurological symptoms after 6 hours are not eligible. The study aims to improve outcomes for this specific population. Participants will be randomly assigned to receive either DM199 or a placebo. The treatment involves a single intravenous dose followed by subcutaneous doses starting 2 hours plus or minus 10 hours after the IV dose, then twice weekly up to Day 21. The study includes an interim analysis after 200 participants complete their 90-day assessment to evaluate safety and potentially adjust the sample size, with up to 728 participants planned. Treatments are administered under careful medical supervision. During the approximately 90-day participation, individuals will undergo various assessments including evaluations of stroke recovery, disability, neurological function, mortality, functional independence, and recurrence of acute ischemic stroke, all measured at Day 90. Participants will be monitored closely through these visits and assessments to track their progress and safety throughout the study and follow-up period.

CONDITIONS

Brief Title

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Research Team

S

Shanique Smythe - Peterkin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here